Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab

Purpose: First-line immune checkpoint blockade has improved the prognosis of recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), but response rates remain low. In this study, we aimed to investigate the prognostic value of CRP and its early kinetics to predict response and...

Descripción completa

Detalles Bibliográficos
Autores principales: Haas, Markus, Lein, Alexander, Fuereder, Thorsten, Schnoell, Julia, Brkic, Faris F., Liu, David T., Kadletz-Wanke, Lorenz, Heiduschka, Gregor, Jank, Bernhard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560194/
https://www.ncbi.nlm.nih.gov/pubmed/37603206
http://dx.doi.org/10.1007/s10637-023-01388-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560194/
https://www.ncbi.nlm.nih.gov/pubmed/37603206
http://dx.doi.org/10.1007/s10637-023-01388-x

Ejemplares similares